scholarly journals Approach to the Assessment and Management of Pediatric Patients With Atopic Dermatitis: A Consensus Document. Section III: Treatment Options for Pediatric Atopic Dermatitis

2019 ◽  
Vol 23 (5_suppl) ◽  
pp. 19S-31S
Author(s):  
Perla Lansang ◽  
Joseph M. Lam ◽  
Danielle Marcoux ◽  
Vimal H. Prajapati ◽  
Shanna Spring ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Maintenance Therapy ◽  
Pediatric Patients ◽  
Treatment Options ◽  
Skin Barrier ◽  
Active Therapy ◽  
Disease Treatment ◽  
Consensus Document ◽  
Emerging Therapies ◽  
Clinical Considerations

Because atopic dermatitis (AD) is a chronic, relapsing disease, treatment requires the use of both active therapy to control flares and preventative maintenance therapy to promote integrity of the skin barrier. In this third of four sections, important clinical considerations for the treatment of pediatric AD are reviewed. Emerging therapies in development for pediatric AD are introduced.

scholarly journals Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document. Section IV: Treatment Options for the Management of Atopic Dermatitis

2018 ◽  
Vol 22 (1_suppl) ◽  
pp. 21S-29S ◽  
Author(s):  
Gurbir Dhadwal ◽  
Lorne Albrecht ◽  
Robert Gniadecki ◽  
Yves Poulin ◽  
Jensen Yeung ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Topical Therapy ◽  
Treatment Options ◽  
Skin Barrier ◽  
Skin Inflammation ◽  
Skin Barrier Function ◽  
Improve Quality ◽  
Consensus Document ◽  
Basic Care

The objectives of therapy for atopic dermatitis (AD) are to reduce skin inflammation and pruritus, restore skin barrier function, and improve quality of life (QoL). Treatments can be classified as moisturizing and basic care, topical therapy, phototherapy, and systemic therapy. In this review, we summarize the treatments for AD and recommendations for their use.

scholarly journals Approach to the Assessment and Management of Pediatric Patients with Atopic Dermatitis: A Consensus Document. Section II: Comorbid Disease in Pediatric Atopic Dermatitis

2019 ◽  
Vol 23 (5_suppl) ◽  
pp. 12S-18S ◽  
Author(s):  
Chih-ho Hong ◽  
Marissa Joseph ◽  
Vy HD Kim ◽  
Perla Lansang ◽  
Irene Lara-Corrales
Keyword(s):  
Atopic Dermatitis ◽  
Health Care Providers ◽  
Pediatric Patients ◽  
Allergic Diseases ◽  
Care Providers ◽  
Barrier Dysfunction ◽  
Consensus Document ◽  
Common Skin ◽  
Genetic And Environmental Factors ◽  
Skin Conditions

Pediatric atopic dermatitis (AD) is one of the most common skin conditions encountered by health-care providers caring for infants, children, and adolescents. Pediatric patients with AD may present with other allergic and nonallergic comorbidities that require appropriate treatment and referral. They may also experience a trajectory of allergic diseases known as the atopic march, which depends on a complex interaction between genetic and environmental factors and likely involves early epidermal barrier dysfunction. Here we provide a review and clinical recommendations on the assessment and referral of comorbidities in pediatric AD.

scholarly journals Pediatric Atopic Dermatitis: Update on the Treatment Options

2020 ◽  
Vol 25 (4) ◽  
pp. 60-62
Author(s):  
Corina Adelina Zah ◽  
Andreea Emiliana Toporău ◽  
Paul Grama
Keyword(s):  
Atopic Dermatitis ◽  
Chronic Treatment ◽  
Pediatric Patients ◽  
Treatment Options ◽  
Chronic Inflammatory Disease ◽  
Term Treatment ◽  
Phosphodiesterase 4 ◽  
Systemic Corticosteroids ◽  
Long Term Treatment

Abstract Atopic dermatitis (AD) is a chronic inflammatory disease characterized by skin dryness, pruritus and eczematous lesions with various periods of relapse. Symptomatology can appear in childhood and can persist in adulthood. Chronic treatment is required with corticosteroids being the standard options. The side effects of this type of long-term treatment represent a major concern for the pediatric patients. This review aims to give an update of the options used for treatment, apart from the systemic corticosteroids. Mild-to-moderate AD had a good response to creams containing fig and oatmeal extracts and inhibitors of phosphodiesterase-4 (crisaborole). In cases of severe AD, future treatment options could include monoclonal antibodies such as omalizumab and dupilumab

Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document. Section I: Pathophysiology of Atopic Dermatitis and Implications for Systemic Therapy

2018 ◽  
Vol 22 (1_suppl) ◽  
pp. 6S-9S ◽  
Author(s):  
Mark G. Kirchhof ◽  
Ian Landells ◽  
Chuck W. Lynde ◽  
Melinda J. Gooderham ◽  
Chih-ho Hong
Keyword(s):  
Atopic Dermatitis ◽  
Environmental Factors ◽  
Chronic Inflammation ◽  
Systemic Therapy ◽  
Skin Disease ◽  
Treatment Options ◽  
Adult Patients ◽  
Inflammatory Skin Disease ◽  
Consensus Document ◽  
Systemic Therapies

Atopic dermatitis (AD) is a chronic, relapsing, and remitting inflammatory skin disease whose onset typically occurs early in life. AD pathophysiology includes genetic, immune, and environmental factors contributing to chronic inflammation. A rapidly evolving understanding of the pathogenesis of AD has led to the development of several treatment options for AD in adults, including topicals, phototherapy, and systemic therapies. Here, we provide a concise summary of AD pathophysiology with a focus on implications for systemic therapy.

scholarly journals Approach to the Assessment and Management of Pediatric Patients With Atopic Dermatitis: A Consensus Document. Section IV: Consensus Statements on the Assessment and Management of Pediatric Atopic Dermatitis

2019 ◽  
Vol 23 (5_suppl) ◽  
pp. 32S-39S
Author(s):  
Perla Lansang ◽  
Irene Lara-Corrales ◽  
James N. Bergman ◽  
Chih-ho Hong ◽  
Marissa Joseph ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Health Care Professionals ◽  
Pediatric Patients ◽  
Pediatric Population ◽  
Extensive Experience ◽  
Modified Delphi ◽  
Consensus Document ◽  
Consensus Statements ◽  
Practical Guidance ◽  
Iterative Voting

This document is intended to provide practical guidance to physicians treating pediatric atopic dermatitis (AD), especially dermatologists, pediatricians, allergists, and other health-care professionals. The recommendations contained here were formalized based on a consensus of 12 Canadian pediatric dermatologists, dermatologists, pediatricians, and pediatric allergists with extensive experience managing AD in the pediatric population. A modified Delphi process was adopted with iterative voting on a 5-point Likert scale, with a prespecified agreement cutoff of 75%. Topic areas addressed in the 17 consensus statements reflect areas of practical management, including counselling, assessment, comorbidity management, and therapy.

Review of Systemic Treatment Options for Adult Atopic Dermatitis

2016 ◽  
Vol 21 (1) ◽  
pp. 31-39 ◽  
Author(s):  
Melinda Gooderham ◽  
Charles W. Lynde ◽  
Kim Papp ◽  
Marc Bourcier ◽  
Lyn Guenther ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Immune Responses ◽  
Systemic Therapy ◽  
Systemic Treatment ◽  
Treatment Options ◽  
Skin Barrier ◽  
New Approach ◽  
Systemic Treatments ◽  
Systemic Therapies

Background: Atopic dermatitis (AD) is a chronic, pruritic inflammatory skin disease resulting from defects in skin barrier and aberrant immune responses. AD significantly affects the quality of life. Not all patients respond to topical therapies, and often systemic therapy is required to control the disease. Objective: To review the treatment options for adult AD patients including those options for patients who do not respond adequately or have contraindications to oral systemic therapy. Methods: A working group of clinicians with experience managing AD was convened to review the current literature on treatment options for adult AD patients. This review is based on the best available evidence from a published systematic review and an additional literature search. Results: Current treatments for AD are reviewed, including options for adult AD patients who do not respond or have contraindications to current systemic therapies. A new approach with targeted therapies is reviewed based on best available evidence. Conclusion: Many AD patients respond satisfactorily to topical or systemic treatments, but for those patients who do not respond or have contraindications, new biologic agents appear to be promising therapies.

scholarly journals SKIN MICROBIOTA AND ATOPIC DERMATITIS IN CHILDREN: NEW TREATMENT OPTIONS

2019 ◽  
Vol 21 (2) ◽  
pp. 106-113
Author(s):  
Galina I. Smirnova ◽  
D. B. Munblit ◽  
A. I. Kolotilina ◽  
D. M. Levina
Keyword(s):  
Atopic Dermatitis ◽  
Treatment Options ◽  
Skin Barrier ◽  
General Concept ◽  
Small Species ◽  
Dry Skin ◽  
Skin Microbiota ◽  
New Treatment ◽  
The Relationship

There are presented data characterizing atopic dermatitis (AD) in children as a form of allergic pathology, directly related to the condition and quality of the microbiota (intestinal and skin) of the growing organism. The microbiota of the affected skin of AD patients is characterized by a small species diversity of bacteria; the decrease in the number of actinomycetes and proteobacteria; increased colonization by various types of staphylococci (etc.). The relationship between the rate of formation of AD and the disturbance of the skin microbiota in children has been established. The concept of the preservation of high biodiversity of microbiota of a growing organism as a strategy for optimizing microecology of children by using adaptive probiotics in a healthy microenvironment is proposed. The restoration of the barrier function of the skin is determined as the most important task included in the general concept of the treatment of AD, where a significant role is assigned to new means of dermatological cosmetics and proper skin care. The possibilities of normalization the microbiota of affected areas of the skin with the help of cosmetic means for the care of dry skin are shown as a result of the restoration of the skin barrier.

scholarly journals Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document. Section V: Consensus Statements on the Assessment and Management of Adult Patients With Moderate-to-Severe Atopic Dermatitis

2018 ◽  
Vol 22 (1_suppl) ◽  
pp. 30S-35S ◽  
Author(s):  
Chih-ho Hong ◽  
Melinda J. Gooderham ◽  
Lorne Albrecht ◽  
Robert Bissonnette ◽  
Gurbir Dhadwal ◽  
...  
Keyword(s):  
Health Care ◽  
Atopic Dermatitis ◽  
Health Care Providers ◽  
Treatment Options ◽  
Adult Patients ◽  
Severe Atopic Dermatitis ◽  
Care Providers ◽  
Extensive Experience ◽  
Consensus Document ◽  
Consensus Statements

This document is a concise, current, and practical guide for dermatologists and other health care providers managing adult patients with moderate-to-severe atopic dermatitis (AD). The recommendations made here are based on a consensus of specialists with extensive experience managing patients with AD. Topics reviewed in this publication include AD pathophysiology, assessment, comorbidities, and treatment options.

scholarly journals Pathophysiology of Atopic Dermatitis and Psoriasis: Implications for Management in Children

Children ◽  
2019 ◽  
Vol 6 (10) ◽  
pp. 108 ◽  
Author(s):  
Chovatiya ◽  
Silverberg
Keyword(s):  
Atopic Dermatitis ◽  
Skin Diseases ◽  
Treatment Options ◽  
Skin Barrier ◽  
T Helper ◽  
T Helper 1 ◽  
Inflammatory Skin Diseases ◽  
Current State ◽  
Related Quality ◽  
Health Related

Atopic dermatitis (AD) and psoriasis are chronic inflammatory skin diseases associated with a significant cutaneous and systemic burden of disease as well as a poor health-related quality of life. Here, we review the complex pathophysiology of both AD and psoriasis and discuss the implications for treatment with current state-of-the-art and emerging topical and systemic therapies. Both AD and psoriasis are caused by a complex combination of immune dysregulation, skin-barrier disruption, genetic factors, and environmental influences. Previous treatments for both diseases were limited to anti-inflammatory agents that broadly suppress inflammation. Emerging insights into relevant pathways, including recognition of the role of T-helper type 2 driven inflammation in AD and T-helper 1 and 17 driven inflammation in psoriasis, have led to a therapeutic revolution. There are a number of novel treatment options available for AD and psoriasis with many more currently under investigation.

Sign in / Sign up

Export Citation Format

Share Document